Cargando…
Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre
In urea cycle disorders (UCDs) ammonia scavenger drugs, usually sodium‐based, have been the mainstay of treatment. Increasingly, glycerol phenylbutyrate (GPB, Ravicti®) is being used but scant real‐world data exist regarding clinical outcomes. A retrospective study of UCD patients initiated on or sw...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494499/ https://www.ncbi.nlm.nih.gov/pubmed/37701329 http://dx.doi.org/10.1002/jmd2.12386 |
_version_ | 1785104706433974272 |
---|---|
author | Yeo, Mildrid Rehsi, Preeya Dorman, Megan Grunewald, Stephanie Baruteau, Julien Chakrapani, Anupam Footitt, Emma Prunty, Helen McSweeney, Melanie |
author_facet | Yeo, Mildrid Rehsi, Preeya Dorman, Megan Grunewald, Stephanie Baruteau, Julien Chakrapani, Anupam Footitt, Emma Prunty, Helen McSweeney, Melanie |
author_sort | Yeo, Mildrid |
collection | PubMed |
description | In urea cycle disorders (UCDs) ammonia scavenger drugs, usually sodium‐based, have been the mainstay of treatment. Increasingly, glycerol phenylbutyrate (GPB, Ravicti®) is being used but scant real‐world data exist regarding clinical outcomes. A retrospective study of UCD patients initiated on or switched to GPB was performed at a UK centre. Data on population characteristics, treatment aspects, laboratory measurements, and clinical outcomes were collected before and after patients started GPB with a sub‐group analysis undertaken for patients with ≥12 months of data before and after starting GPB. UCDs included arginosuccinate synthetase deficiency (n = 8), arginosuccinate lyase deficiency (n = 6), ornithine carbamoyltransferase deficiency (n = 3), and carbamoyl phosphate synthetase 1 deficiency (n = 3). In the sub‐group analysis (n = 11), GPB resulted in lower plasma ammonia (31 vs. 41 μmol/L, p = 0.037), glutamine (670 vs. 838 μmol/L, p = 0.002), annualised hyperammonaemic episodes (0.2 vs. 1.9, p = 0.020), hospitalisations (0.5 vs. 2.2, p = 0.010), and hyperammonaemic episodes resulting in hospitalisation (0.2 vs. 1.6, p = 0.035) reflecting changes seen in the whole group. Overall, patients exposed to sodium and propylene glycol levels above UK daily limits reduced by 78% and 83% respectively. Mean levels of branched chain amino acids, haemoglobin, and white cell count were unchanged. Two adverse drug reactions (pancytopenia, fatigue/appetite loss) resolved without GPB discontinuation. Patients/families preferred GPB for its lower volume, greater palatability and easier administration. GPB appeared to improve biochemical measures and clinical outcomes. The causes are multi‐factorial and are likely to include prolonged action of GPB and its good tolerability, even at higher doses, facilitating tighter control of ammonia. |
format | Online Article Text |
id | pubmed-10494499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104944992023-09-12 Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre Yeo, Mildrid Rehsi, Preeya Dorman, Megan Grunewald, Stephanie Baruteau, Julien Chakrapani, Anupam Footitt, Emma Prunty, Helen McSweeney, Melanie JIMD Rep Case Reports In urea cycle disorders (UCDs) ammonia scavenger drugs, usually sodium‐based, have been the mainstay of treatment. Increasingly, glycerol phenylbutyrate (GPB, Ravicti®) is being used but scant real‐world data exist regarding clinical outcomes. A retrospective study of UCD patients initiated on or switched to GPB was performed at a UK centre. Data on population characteristics, treatment aspects, laboratory measurements, and clinical outcomes were collected before and after patients started GPB with a sub‐group analysis undertaken for patients with ≥12 months of data before and after starting GPB. UCDs included arginosuccinate synthetase deficiency (n = 8), arginosuccinate lyase deficiency (n = 6), ornithine carbamoyltransferase deficiency (n = 3), and carbamoyl phosphate synthetase 1 deficiency (n = 3). In the sub‐group analysis (n = 11), GPB resulted in lower plasma ammonia (31 vs. 41 μmol/L, p = 0.037), glutamine (670 vs. 838 μmol/L, p = 0.002), annualised hyperammonaemic episodes (0.2 vs. 1.9, p = 0.020), hospitalisations (0.5 vs. 2.2, p = 0.010), and hyperammonaemic episodes resulting in hospitalisation (0.2 vs. 1.6, p = 0.035) reflecting changes seen in the whole group. Overall, patients exposed to sodium and propylene glycol levels above UK daily limits reduced by 78% and 83% respectively. Mean levels of branched chain amino acids, haemoglobin, and white cell count were unchanged. Two adverse drug reactions (pancytopenia, fatigue/appetite loss) resolved without GPB discontinuation. Patients/families preferred GPB for its lower volume, greater palatability and easier administration. GPB appeared to improve biochemical measures and clinical outcomes. The causes are multi‐factorial and are likely to include prolonged action of GPB and its good tolerability, even at higher doses, facilitating tighter control of ammonia. John Wiley & Sons, Inc. 2023-07-23 /pmc/articles/PMC10494499/ /pubmed/37701329 http://dx.doi.org/10.1002/jmd2.12386 Text en © 2023 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Yeo, Mildrid Rehsi, Preeya Dorman, Megan Grunewald, Stephanie Baruteau, Julien Chakrapani, Anupam Footitt, Emma Prunty, Helen McSweeney, Melanie Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre |
title | Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre |
title_full | Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre |
title_fullStr | Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre |
title_full_unstemmed | Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre |
title_short | Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre |
title_sort | clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a uk paediatric centre |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494499/ https://www.ncbi.nlm.nih.gov/pubmed/37701329 http://dx.doi.org/10.1002/jmd2.12386 |
work_keys_str_mv | AT yeomildrid clinicalexperiencewithglycerolphenylbutyratein20patientswithureacycledisordersataukpaediatriccentre AT rehsipreeya clinicalexperiencewithglycerolphenylbutyratein20patientswithureacycledisordersataukpaediatriccentre AT dormanmegan clinicalexperiencewithglycerolphenylbutyratein20patientswithureacycledisordersataukpaediatriccentre AT grunewaldstephanie clinicalexperiencewithglycerolphenylbutyratein20patientswithureacycledisordersataukpaediatriccentre AT baruteaujulien clinicalexperiencewithglycerolphenylbutyratein20patientswithureacycledisordersataukpaediatriccentre AT chakrapanianupam clinicalexperiencewithglycerolphenylbutyratein20patientswithureacycledisordersataukpaediatriccentre AT footittemma clinicalexperiencewithglycerolphenylbutyratein20patientswithureacycledisordersataukpaediatriccentre AT pruntyhelen clinicalexperiencewithglycerolphenylbutyratein20patientswithureacycledisordersataukpaediatriccentre AT mcsweeneymelanie clinicalexperiencewithglycerolphenylbutyratein20patientswithureacycledisordersataukpaediatriccentre |